Cell membrane-based nanomaterials for therapeutics of neurodegenerative diseases

Neurochemistry International, Journal Year: 2023, Volume and Issue: 170, P. 105612 - 105612

Published: Sept. 15, 2023

Language: Английский

---

Polymeric nanoparticles: A promising strategy for treatment of Alzheimer's disease

Journal of Taibah University Medical Sciences, Journal Year: 2024, Volume and Issue: 19(3), P. 549 - 565

Published: April 26, 2024

si ty M e di c al S ci n s , 1 9 (3).

---

Nanomaterials that Aid in the Diagnosis and Treatment of Alzheimer's Disease, Resolving Blood–Brain Barrier Crossing Ability

Advanced Science, Journal Year: 2024, Volume and Issue: 11(38)

Published: Aug. 5, 2024

As a form of dementia, Alzheimer's disease (AD) suffers from no efficacious cure, yet AD treatment is still imperative, as it ameliorates the symptoms or prevents deteriorating maintains current status to longest extent. The human brain most sensitive and complex organ in body, which protected by blood-brain barrier (BBB). This induces difficulty curing drugs nanomaterials that are much inhibited reaching lesion site. Thus, BBB crossing capability drug delivery system remains significant challenge development neurological therapeutics. Fortunately, nano-enabled systems possess promising potential achieve multifunctional diagnostics/therapeutics against various targets owing their intriguing advantages nanocarriers, including easy multifunctionalization on surfaces, high surface-to-volume ratio with large payloads, ability cross BBB, making them capable conquering limitations conventional candidates. review, focuses diagnosis treatment, will provide an insightful vision conducive AD-related nanomaterials.

Language: Английский

---

Upregulation of Ca2+-binding proteins contributes to VTA dopamine neuron survival in the early phases of Alzheimer’s disease in Tg2576 mice

Molecular Neurodegeneration, Journal Year: 2022, Volume and Issue: 17(1)

Published: Nov. 25, 2022

Recent clinical and experimental studies have highlighted the involvement of Ventral Tegmental Area (VTA) dopamine (DA) neurons for early pathogenesis Alzheimer's Disease (AD). We previously described a progressive selective degeneration these in Tg2576 mouse model AD, long before amyloid-beta plaque formation. The degenerative process DA is associated with an autophagy flux impairment, whose rescue can prevent neuronal loss. Impairments be basis accumulation damaged mitochondria, leading to disturbance calcium (Ca2+) homeostasis, functional structural deterioration neurons.In mice, we performed amperometric recordings levels analysis dopaminergic fibers Nucleus Accumbens - major component ventral striatum precociously affected AD patients together retrograde tracing, identify most vulnerable neuron subpopulations VTA. Then, focused on analyze mitochondrial integrity Apoptosis-inducing factor (AIF) localization by electron confocal microscopy, respectively. Stereological cell count was also used evaluate containing Ca2+-binding proteins Calbindin-D28K Calretinin. expression were analyzed western blot microscopy. Lastly, using electrophysiology microfluorometry VTA intrinsic properties cytosolic free Ca2+ levels.We found mesolimbic projecting striatum, located paranigral nucleus parabrachial pigmented subnucleus At onset (3 months age), accumulate while AIF translocates from mitochondria nucleus. Although describe age-dependent loss expressing or Calretinin, observed that remaining cells upregulate proteins, are significantly decreased. Coherently, TUNEL-stained express lower when compared non-apoptotic cells.Overall, our results suggest overexpression might attempt survive increasing their ability buffer Ca2+. Exploring strategies overexpress could fundamental reduce suffering improve cognitive non-cognitive functions AD.

Language: Английский

---

Role of Exosomes in the Pathogenesis and Theranostic of Alzheimer’s Disease and Parkinson’s Disease

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(13), P. 11054 - 11054

Published: July 4, 2023

Alzheimer’s disease (AD) and Parkinson’s (PD) are the most common neurodegenerative diseases (NDDs) threatening lives of millions people worldwide, including especially elderly people. Currently, due to lack a timely diagnosis proper intervention strategy, AD PD largely remain incurable. Innovative therapy highly desired. Exosomes small vesicles that present in various bodily fluids, which contain proteins, nucleic acids, active biomolecules, play crucial role intercellular communication. In recent years, exosomes pathogenesis, early diagnosis, treatment has attracted ascending attention. However, exact pathogenesis theragnostic not been fully illustrated. review, we first introduce biogenesis, components, uptake, function exosomes. Then elaborate on involvement PD. Moreover, application therapeutics is also summarized discussed. Additionally, serving as drug carriers deliver medications central nervous system specifically addressed. The potential explored, discussing their applications treatment, well current limitations. Given limitation exosomes, propose future perspectives for better utilizing NDDs. Hopefully, it would pave ways expanding biological fundamental research theranostics

Language: Английский

---

Borneol-Modified Schisandrin B Micelles Cross the Blood–Brain Barrier To Treat Alzheimer’s Disease in Aged Mice

ACS Chemical Neuroscience, Journal Year: 2024, Volume and Issue: 15(3), P. 593 - 607

Published: Jan. 12, 2024

Objective: Schisandrin B (Sch B) is a bioactive dibenzocyclooctadiene derizative that prevalent in the fruit of Schisandra chinensis. Numerous studies have demonstrated Sch has neuroprotective action by reducing oxidative stress and effectively preventing inflammation. It follows potential treatment for Alzheimer's disease (AD). However, drug's solubility, bioavailability, lower permeability blood–brain barrier (BBB) can all reduce its efficacy during therapy process. Therefore, this study constructed borneol-modified schisandrin micelles (Bor-Sch B-Ms), which increase brain targeting accurately delivering medications to brain, improving bioavailability. High therapeutic been achieved at pathological site. Methods: Bor-Sch B-Ms were prepared using thin film dispersion approach article. On one hand, observe effect borneol, we model vitro studied ability cross BBB. other distribution micelle drugs their related pharmacological effects on neuroinflammation, stress, neuronal damage through vivo administration mice. Results: In drug uptake bEnd.3 cells was increased borneol alteration surface nano micelles, implying promote N2a cells. This could result more medicines entering addition, revealed circulation time tissue significantly higher than those groups, making it suitable central nervous system diseases. Conclusion: As novel nanodrug delivery system, modified promising research prospects disease.

Language: Английский

---

Neuroprotective Role of Phytoconstituents-based Nanoemulsion for the Treatment of Alzheimer’s Disease

Current Topics in Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 24(19), P. 1683 - 1698

Published: April 27, 2024

: Alzheimer's disease (AD) is the most prevalent form of neurodegenerative disorder (ND), affecting more than 44 million individuals globally as 2023. It characterized by cognitive dysfunction and an inability to perform daily activities. The progression AD associated with accumulation amyloid beta (Aβ), formation neurofibrillary tangles (NFT), increased oxidative stress, neuroinflammation, mitochondrial dysfunction, endoplasmic reticulum stress. Presently, various phytomedicines their bioactive compounds have been identified for neuroprotective effects in reducing alleviating mitigating Aβ acetylcholinesterase enzymes hippocampus cerebral cortex regions brain. However, despite demonstrating promising anti-Alzheimer's effects, clinical utilization phytoconstituents remains limited scope. key factor contributing this limitation challenges inherent traditional drug delivery systems, which impede effectiveness efficiency. These difficulties encompass insufficient targeting, restricted solubility stability, brief duration action, a lack control over release. Consequently, these constraints result diminished bioavailability permeability across blood-brain barrier (BBB). In response challenges, novel systems (NDDS) founded on nanoformulations emerged hopeful strategy augment BBB poor solubility. Among nanoemulsion (NE) extensively investigated potential targeting AD. NE offers several advantages, such ease preparation, high loading, stability. Due nanosize droplets, also improves gut leading enhanced systemic circulation Various studies reported testing NE-based bioactives different animal species, including transgenic, Wistar, Sprague-Dawley (SD) rats, well mice. transgenic mice are commonly employed research analyze Aβ. review, aspects role phytoconstituents, conventional delivery, need NDDS, particularly NE, discussed. involving phytoconstituent-based treatment

Language: Английский

---

Breaking the barriers in management of Alzheimer's disease through cationic nanoformulation: A review

Results in Chemistry, Journal Year: 2024, Volume and Issue: 7, P. 101463 - 101463

Published: Jan. 1, 2024

Neurodegenerative Alzheimer's disease (AD) leads to cognitive and behavioral decline. The current crop of FDA-approved treatments for AD can only reduce symptoms postpone the disease's progression by facilitating communication between neurons in brain patient. Any potential treatment should inflammation, prevent acetylcholine hydrolysis, act as an antioxidant. Traditional treatments, such acetylcholinesterase inhibitors, frequently fall short their intended effects due solubility, bioavailability, blood–brain barrier (BBB) bridging. Therapy failure is caused inadequate pharmacokinetics pharmacodynamics commonly used medications. Systemic delivery central nervous system using cationic nanosized carriers a promising area research. Adsorption-mediated translocation refers ability interrelate electrostatically with cell membranes that are negatively charged cross BBB through endocytosis or adsorption-mediated transcytosis. Cationic nanopharmaceuticals (CNPs) showed treating in-vivo following systemic administration. transcytosis across be easily facilitated lipids, increasing mucoadhesion nasal cavity enhancing electrostatic interactions mucus. Nano-cationic formulations' dimensions, elasticity, hydrophobicity, surface charge, chemistry, morphology significantly impact journey. In this review state nanoformulation targeting future directions approach have been briefly discussed dricption fill gap knowledge.

Language: Английский

---

Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: Jan. 29, 2025

Neurodegenerative diseases, characterized by progressive neuronal loss and cognitive impairments, pose a significant global health challenge. This study explores the potential of nanotherapeutics as promising approach to enhance drug delivery across physiological barriers, particularly blood–brain barrier (BBB) blood-cerebrospinal fluid (B-CSFB). By employing nanoparticles, this research aims address critical challenges in diagnosis treatment conditions such Alzheimer’s, Parkinson’s, Huntington’s diseases. The multifactorial nature these disorders necessitates innovative solutions that leverage nanomedicine improve solubility, circulation time, targeted while minimizing off-target effects. findings underscore importance advancing applications develop effective therapeutic strategies can alleviate burden neurodegenerative diseases on individuals healthcare systems.

Language: Английский

---

Nanotechnology in Parkinson’s Disease: overcoming drug delivery challenges and enhancing therapeutic outcomes

Drug Delivery and Translational Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 29, 2025

Language: Английский

---